Physician profile
Inga Benson
NPI 1699932293
$4,947.61
in general payments reported to CMS, 2019-2025
22 companies · $651 in 2025
The $651 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,303 · 2022: $954 · 2023: $910 · 2024: $1,129 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $782.01 | 2021-2025 | |
| Abbvie INC. | $707.48 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $571.04 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $551.39 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.54 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $322.78 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Astrazeneca Pharmaceuticals LP | $314.73 | 2021-2024 | Lokelma |
| Novo Nordisk INC | $291.62 | 2023-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.32 | 2023-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $169.39 | 2021-2024 | Eliquis, Camzyos |
| Melinta Therapeutics, LLC | $131.18 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $104.42 | 2021-2025 | Ultomiris |
| Gilead Sciences, INC. | $87.95 | 2021-2024 | |
| Boston Scientific Corporation | $70.62 | 2021-2024 | Watchman Flx |
| Sk Life Science, INC. | $60.25 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $26.94 | 2021 | |
| Abbott Laboratories | $24.94 | 2024 | Mitraclip |
| Paratek Pharmaceuticals, INC. | $24.79 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.13 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Amgen INC. | $17.11 | 2024 | Repatha |
| Electromed, INC. | $13.78 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inga Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.